In units with high rates of resistance empirical use of colistin in the treatment of late ventilator-associated pneumonia cannot be recommended. ( Cisneros JM. et al. )

Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial.

| Dr Olivier Leroy

Multidrug-resistant gram-negative bacilli (MDR-GNB), including Pseudomonas aeruginosa, Acinetobacter baumannii, and extended-spectrum beta-lactamase (ESBL)-producing or carbapenemase-producing Enterobacteriaceae, are currently the pathogens … Suite  

Does Colistin-Meropenem combination therapy reduce the emergence of colistin resistance vs. Colistin monotherapy? ( Dickstein Y. et al. & AIDA study group. )

Colistin Resistance Development Following Colistin-Meropenem Combination Therapy vs. Colistin Monotherapy in Patients with Infections Caused by Carbapenem-Resistant Organisms.

| Dr Jean-Pierre Bru

Colistin is one of a limited number of options for the treatment of carbapenem-resistant Gram-negative bacteria. A previously published randomized … Suite